Edgewise director granted 16,377 stock options

Edgewise Therapeutics director and 10% owner Peter A. Thompson received a grant of stock options for 16,377 shares of common stock.

Rhea-AI Filing Summary

Edgewise Therapeutics director and 10% owner Peter A. Thompson received a grant of stock options for 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036.

According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Thompson holds 16,377 stock options directly.

Insider Trade Summary

Grant/Award: 16,377 shares

Grant/Award 1 txn

Insider Thompson Peter A.

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,377	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,377 contracts (Direct)

Footnotes (1)

1. F1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Key Figures

Options granted: 16,377 options Exercise price: $35.59 per share Expiration date: June 5, 2036 +2 more

5 metrics

Options granted 16,377 options Stock Option (Right to Buy) grant on June 5, 2026

Exercise price $35.59 per share Conversion or exercise price of stock options

Expiration date June 5, 2036 Option term end for granted stock options

Underlying shares 16,377 shares Common stock underlying granted options

Post-grant derivative holdings 16,377 options Total stock options held following the transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vested, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "35.5900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"100% of the Stock Options granted on June 5, 2026 will become vested"

annual meeting of stockholder financial

"prior to the 2027 annual meeting of stockholder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edgewise Therapeutics (EWTX) report for Peter A. Thompson?

Edgewise Therapeutics reported that director and 10% owner Peter A. Thompson received a grant of 16,377 stock options. These options give him the right to buy Edgewise common shares at a fixed exercise price in the future, subject to vesting conditions.

How many Edgewise Therapeutics (EWTX) stock options were granted to Peter A. Thompson?

Peter A. Thompson was granted 16,377 stock options linked to Edgewise Therapeutics common stock. Each option represents the right to purchase one share once vested, providing potential future equity exposure if the market price exceeds the exercise price.

What is the exercise price of Peter A. Thompson’s Edgewise Therapeutics (EWTX) stock options?

The granted stock options have an exercise price of $35.59 per share. This means Thompson can buy Edgewise Therapeutics common shares at $35.59 per share upon exercise after vesting, regardless of the market price at that time.

When do Peter A. Thompson’s Edgewise Therapeutics (EWTX) stock options vest?

All of the granted stock options will vest 100% on the earlier of June 5, 2027 or the business day before Edgewise Therapeutics’ 2027 annual stockholder meeting. Vesting must occur before Thompson can exercise the options to acquire shares.

What is the expiration date of the Edgewise Therapeutics (EWTX) stock options granted to Peter A. Thompson?

The stock options granted to Peter A. Thompson expire on June 5, 2036. After this expiration date, any unexercised options become void, so exercise must occur between vesting and that expiration date to acquire common shares.

How many Edgewise Therapeutics (EWTX) stock options does Peter A. Thompson hold after this grant?

Following this transaction, Peter A. Thompson holds 16,377 stock options directly. This figure reflects his derivative holdings from this specific grant reported in the filing and represents potential future rights to acquire Edgewise common stock if exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Peter A.

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.59	06/05/2026		A		16,377		06/02/2027(1)	06/05/2036	Common Stock	16,377	$0.00	16,377	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Remarks:

	/s/ John R. Moore Attorney-in-Fact for Peter Thompson M.D.	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)